Patents by Inventor PATRICK CHENE
PATRICK CHENE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210299100Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: March 15, 2021Publication date: September 30, 2021Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Zhongbo FEI, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Jialiang LI, Wei LI, Edwige Liliane Jeanne LORTHIOIS, Joseph McKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
-
Publication number: 20160220576Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: April 12, 2016Publication date: August 4, 2016Applicant: Novartis AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20160045513Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: October 28, 2015Publication date: February 18, 2016Applicant: Novartis AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20140288075Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: May 2, 2014Publication date: September 25, 2014Applicant: Novartis AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20120214813Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: May 2, 2012Publication date: August 23, 2012Applicant: NOVARTIS AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20120083496Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: December 8, 2011Publication date: April 5, 2012Applicant: NOVARTIS AGInventors: Patrick CHENE, Carlos GARCIA-ECHEVERRIA, Michael Rugaard JENSEN, Cornelia QUADT, Thomas RADIMERSKI, Joseph SCHOEPFER
-
Publication number: 20100210650Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: October 10, 2008Publication date: August 19, 2010Applicant: NOVARTIS AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20090069341Abstract: The invention relates to the use of benzoimidazolone compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising benzoimidazolone compounds, novel benzoimidazolone compounds, and a process for the preparation of the novel benzoimidazolone compounds.Type: ApplicationFiled: July 26, 2005Publication date: March 12, 2009Inventors: Patrick Chene, Andreas Floersheimer, Pascal Furet, Joseph Schoepfer
-
Publication number: 20090039811Abstract: The invention relates to the use of 1H-indazol-6-ol compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 1H-indazol-6-ol compounds, novel 1H-indazol-6-ol compounds, and a process for the preparation of the novel 1H-indazol-6-ol compounds.Type: ApplicationFiled: July 26, 2005Publication date: February 12, 2009Inventors: Patrick Chene, Andreas Floersheimer, Pascal Furet, Joseph Schoepfer
-
Publication number: 20080311038Abstract: The present invention relates to novel radicicol derivatives of the formula I, in which R is R?, (CH2)nCOOR? or (CH2)nCONHR?, wherein R? is 11CH3, [3H]3C, [3H]2HC, [3H]H2C or (CH2)nHal, wherein Hal is 123I, 125I, 131I, I, 75Br, 76Br, 77Br, 82Br, Br, 18F or F, or R? is (CH2)n-1[3H]HCHal or (CH2)n-1[3H]2CHal, wherein Hal is I, Br or F, and n is, each independently, 1, 2, 3 or 4, in free form or in salt form, to their preparation, to their use as radiotracers/markers and to compositions containing them.Type: ApplicationFiled: January 2, 2007Publication date: December 18, 2008Inventors: Yves Auberson, Mats Bergstroem, Emmanuelle Briard, Patrick Chene, Laurent Martarello, Joseph Schoepfer
-
Publication number: 20070249639Abstract: The invention relates to the use of 9H-purine-2,6-diamine compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 9H-purine-2,6-diamine compounds, novel 9H-purine-2,6-diamine compounds, and a process for the preparation of the novel 9H-purine-2,6-diamine compounds.Type: ApplicationFiled: April 4, 2005Publication date: October 25, 2007Inventors: Rolf Baenteli, Patrick Chene, Stephen Collingwood, Pascal Furet, Peter Meier, Joseph Schoepfer
-
Patent number: 7083983Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.Type: GrantFiled: July 4, 1997Date of Patent: August 1, 2006Assignee: Cancer Research Campaign Technology LimitedInventors: David Philip Lane, Volker Böttger, Angelika Böttger, Steven Michael Picksley, Heinz-Kurt Hochkeppel, Carlos Garcia-Echeverria, Patrick Chène, Pascal Furet
-
Publication number: 20050137137Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.Type: ApplicationFiled: August 25, 2004Publication date: June 23, 2005Inventors: David Lane, Volker Bottger, Angelika Bottger, Steven Picksley, Heinz-Kurt Hochkeppel, Carlos Garcia-Echeverria, Patrick Chene, Pascal Furet
-
Patent number: 6492116Abstract: The present invention concerns a new assay which allows the identification of compounds which inhibit the formation of complexes between a product of the double minute 2 gene (“dm2”) and p53 but not between p53 and DNA. Both the complex formation of labeled DNA, C-terminally truncated p53 and dm2 and disruption of dm2 from the labeled DNA-p53 complex by an inhibitor of the p53-dm2 interaction can be detected by a gel shift assay procedure. This assay permits the selection of compounds which, besides their inhibitory property, do not alter p53 specific DNA binding and do not disturb p53 conformation required for DNA binding or formation of active tetramer.Type: GrantFiled: June 26, 2000Date of Patent: December 10, 2002Assignee: Cancer Research Campain Technology Ltd.Inventors: Patrick Chène, Heinz-Kurt Hochkeppel
-
Publication number: 20010018511Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounsa, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild typr p53 suppressor by interfering with the interaction between human p53 and human MDM2.Type: ApplicationFiled: March 26, 1999Publication date: August 30, 2001Inventors: DAVID LANE, VOLKER BOTTGER, ANGELIKA BOTTGER, STEVEN MICHAEL PICKSLEY, HEINZ-KURT HOCHKEPPEL, CARLOS GARCIA-ECHEVERRIA, PATRICK CHENE, PASCAL FURET